Načítá se...
Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin
Here, we describe the development of a series of highly selective PAR4 antagonists with nanomolar potency and selectivity versus PAR1, derived from the indole-based 3. Of these, 9j (PAR4 IC(50) = 445 nM, PAR1 response IC(50) > 30 µM) and 10h (PAR4 IC(50) = 179 nM, PAR1 response IC(50) > 30 µM)...
Uloženo v:
| Vydáno v: | J Med Chem |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5775816/ https://ncbi.nlm.nih.gov/pubmed/27482618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.6b00928 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|